EMPLICITI ( Uses, Doses, Side effects )

Elotuzumab is a humanized recombinant monoclonal antibody directed against SLAMF7, a cell surface glycoprotein. Elotuzumab consists of the complementarity determining region (CDR) of the mouse antibody MuLuc63, which is grafted onto the framework of the human IgG1 heavy chain and kappa light chain. Elotuzumab is produced in NS0 cells by recombinant DNA technology. The theoretical mass of the intact antibody of Eclozumab is 148.1 kDa.

EMPLICITI (Elocizumab) is a sterile, pyrogen-free, preservative-free lyophilized powder that is white to off-white in a single-dose vial, whole or fragmented cakes. EMPLICITI for injection is provided at the price of 300 mg per bottle and 400 mg per bottle, and needs to be formulated with sterile water for injection USP (13 mL and 17 mL, respectively) to obtain a solution with a concentration of 25 mg/mL. After reconstitution, each vial contains excess filling to allow 12 mL (300 mg) and 16 mL (400 mg) to be pumped. named patient program, The reconstituted solution is colorless to slightly yellow, transparent to slightly opalescent. Before intravenous infusion, dilute the reconstituted solution with 0.9% Sodium Chloride Injection USP or 5% Dextrose Injection USP [see Dosage and Usage].

Each EMPLICITI 300 mg single-dose vial also contains the following inactive ingredients: citric acid monohydrate (2.44 mg), polysorbate 80 (3.4 mg), sodium citrate (16.6 mg) and sucrose (510 mg).

Each EMPLICITI 400 mg single-dose vial also contains the following inactive ingredients: citric acid monohydrate (3.17 mg), polysorbate 80 (4.4 mg), sodium citrate (21.5 mg) and sucrose (660 mg).